California High Court Weighs Gilead’s Liability to 24,000 HIV Patients Over TAF
Gilead Sciences is appealing a California Supreme Court case filed by about 24,000 HIV patients who allege negligence over halting development of its tenofovir alafenamide fumarate (TAF) despite fewer side effects. A ruling could impose a “duty to innovate” product liability, potentially requiring costly continued drug development.
1. Case Overview
The California Supreme Court is set to review whether manufacturers of drugs deemed safe have a legal obligation to continue developing allegedly safer alternatives. This follows lower court rulings allowing negligence claims by patients who used Gilead’s tenofovir disoproxil fumarate (TDF).
2. Gilead’s Argument
Gilead Sciences argues that imposing liability for failing to commercialize marginally improved products would stifle innovation and discourage investment in new therapies. The company warns that a ‘duty to innovate’ could force disclosure of development-stage information and raise R&D costs.
3. Patients’ Allegations
Approximately 24,000 HIV patients claim Gilead discontinued TAF development in 2004 to protect TDF revenues and patent value, delaying a safer alternative until after TDF’s patent expired in 2017. They seek damages for additional harm suffered from prolonged TDF use.
4. Implications for Drugmakers
A decision enforcing a duty to innovate could reshape product liability law, potentially compelling drugmakers to invest in and commercialize incremental drug improvements. Industry stakeholders are monitoring the outcome for its broader impact on pharmaceutical R&D strategies.